Merck Sees No Need To Change Strategy On Mergers
This article was originally published in The Pink Sheet Daily
Executive Summary
Many Vioxx scientists and sales force members will be re-deployed to other projects at Merck, company says. Withdrawal does not change the company's strategy of avoiding mega-mergers, CEO Gilmartin says. Company expects earnings per share shortfall of 50¢ to 60¢, but expects to maintain its current dividend.